PA
CGAU

PharVision Advisers’s Centerra Gold CGAU Stock Holding History

PharVision Advisers’s Portfolio CGAU Stock Details CGAU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,410
Closed -$193K – 200
2025
Q4 		$193K Buy
+13,410
New +$168K 0.1% 572

Other funds holding CGAU

VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LC
L1 Capital Melbourne VIC 3000, Australia $2.55B AUM 80.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $3.68B AUM 62.12% 1-Year Est. Return

PharVision Advisers's CGAU Position: Q1 2026 in Review

PharVision Advisers sold out of Centerra Gold (CGAU) in Q1 2026, closing a stake of 13,410 shares — an estimated $193K sold.

PharVision Advisers first reported a position in CGAU in Q4 2025 and held it in 1 quarter. The position peaked at $193K in Q4 2025. 201 funds tracked by Wall St. Rank hold CGAU as of Q1 2026.

  • PharVision Advisers reported no remaining Centerra Gold position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 13,410 Centerra Gold shares in Q1 2026, an estimated $193K.
  • PharVision Advisers first reported a position in Centerra Gold in Q4 2025 and held it in 1 quarter.
  • PharVision Advisers's Centerra Gold position peaked at $193K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Centerra Gold as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.